AstraZeneca PLC (AZN)vsSerina Therapeutics Inc (SER)
AZN
AstraZeneca PLC
$185.95
-1.94%
HEALTHCARE · Cap: $282.69B
SER
Serina Therapeutics Inc
$1.88
+1.08%
HEALTHCARE · Cap: $26.40M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 46491438% more annual revenue ($60.44B vs $130,000). AZN leads profitability with a 17.2% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
SER
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Margin of Safety
-27.4%
Fair Value
$1.46
Current Price
$1.88
$0.42 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Revenue surging 154.9% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
ROE of -120.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : SER
The strongest argument for SER centers on Revenue Growth, Debt/Equity. Revenue growth of 154.9% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : SER
The primary concerns for SER are Market Cap, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while SER is a hypergrowth play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.21 — expect wider price swings.
SER is growing revenue faster at 154.9% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 26/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Serina Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Serina Therapeutics Inc is a pioneering biotechnology company focused on developing innovative solutions for unmet medical needs in oncology and neurology through its proprietary polymer-based drug delivery platform. This technology significantly enhances the efficacy of therapeutic agents, positioning Serina at the forefront of the biopharmaceutical industry. With a promising pipeline of product candidates and strategic partnerships, the company is well-equipped to drive sustainable growth and deliver impactful healthcare solutions, all while creating substantial value for its investors.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?